These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24182755)

  • 1. Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy.
    Ziada A; Schwarz UI; DeGorter MK; Tirona RG; Ban MR; Kim RB; Hegele RA
    Can J Cardiol; 2013 Nov; 29(11):1395-9. PubMed ID: 24182755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
    Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients.
    Suzuki H; Watanabe Y; Kumagai H; Shuto H
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):306-15. PubMed ID: 24280596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
    Gupta M; Szmitko PE; Tsigoulis M; Braga MF; Kajil M; Herjikaka S; Quan A; Teoh H; Verma S
    J Cardiovasc Pharmacol; 2010 Sep; 56(3):241-5. PubMed ID: 20505518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.
    Meyers CD; Moon YS; Ghanem H; Wong ND
    Ann Pharmacother; 2006 May; 40(5):818-23. PubMed ID: 16638916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors.
    Makkar KM; Sanoski CA; Goldberg LR; Spinler SA
    Ann Pharmacother; 2013 Nov; 47(11):1457-62. PubMed ID: 24285762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
    Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
    Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
    Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for cholesterol hyperabsorbers and hyperproducers based on comparative low-density lipoprotein reductions achieved by ezetimibe versus statins.
    Senaratne J; Griffiths J; MacDonald K; Senaratne MP
    J Cardiopulm Rehabil Prev; 2012; 32(5):250-4. PubMed ID: 22785146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe: a novel option for lowering cholesterol.
    Davidson MH
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.
    Pitsavos C; Skoumas I; Tousoulis D; Metalinos G; Masoura C; Chrysohoou C; Papadimitriou L; Giotsas N; Toutouza M; Antoniades C; Stefanadis C
    Int J Cardiol; 2009 May; 134(2):280-1. PubMed ID: 18353459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.